Nebido (Testosterone Undecanoate)

Testosterone undecanoate is a long‑acting prodrug. After intramuscular injection it is gradually hydrolyzed to testosterone, which then binds intracellular androgen receptors. This binding triggers gene transcription that promotes anabolic processes, erythropoiesis, and the maintenance of male secondary sexual characteristics.

The prescribing physician determines the dose and injection interval based on the individual’s clinical condition, serum testosterone levels, and response to therapy. Dosing is individualized and should follow the healthcare professional’s recommendation.

Nebido is not indicated for use in women, and its safety in pregnancy or breastfeeding is unknown. It should be avoided in these populations, and women of child‑bearing potential should use effective contraception while receiving testosterone therapy.

To order Nebido, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Nebido provides a much longer dosing interval than short‑acting injectables such as testosterone enanthate or cypionate, which often require weekly or bi‑weekly injections. Compared with transdermal gels, Nebido eliminates daily application but requires intramuscular administration. The choice depends on patient preference, adherence, and clinical considerations.

Nebido should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any product that has been exposed to temperatures outside the recommended range.

Nebido is given as an intramuscular injection, typically into a deep gluteal muscle. The injection should be performed by a qualified healthcare professional using aseptic technique. The volume per vial is 3 mL, containing 1000 mg of testosterone undecanoate.

Serious risks include cardiovascular events such as myocardial infarction or stroke, polycythemia (excessive rise in red blood cell mass), liver toxicity, and potential aggravation of pre‑existing prostate cancer. Patients should be monitored regularly for these conditions, and therapy should be discontinued if severe adverse events occur.

Nebido is contraindicated in individuals with known hypersensitivity to testosterone undecanoate, active prostate or breast cancer, severe untreated sleep apnea, uncontrolled hypertension, or a hematocrit above the normal range. It should also be avoided in women, especially during pregnancy or lactation.